Properties and Performance of Epoxy Resin/Boron Acid Composites

This research study focused on the effect of adding boric acid to epoxy resin in order to obtain a composite material with improved properties and performance. To this end, a fine powder of boric acid (H3BO3) was introduced into epoxy resin in different amounts, i.e., 0.5 g, 1.0 g, and 1.5 g. As the matrix of the epoxy composites, styrene-modified epoxy resin based on bisphenol A (BPA) (Epidian 53) was used. It was cross-linked with two types of curing agents, i.e., an amine (ET) and a polyamide (PAC). The mechanical properties of the obtained epoxy composites (in terms of compressive strength, compressive modulus, and compressive strain) were determined at room temperature in order to assess the effect of the addition of boron acid and of the type of curing agent employed to cure the epoxy on these characteristics. Calorimetric measurements were made to highlight any changes in the glass transition temperature (Tg) as a result of the addition of boric acid to epoxy resin. Finally, flammability tests were performed on both Epidian 53/PAC and Epidian 53/ET epoxy composites to analyze their fire behavior and consequently establish the effectiveness of the selected additive as a flame retardant.

Development of an Antibiotic Resistance Breaker to Resensitize Drug-Resistant Staphylococcus aureus: In Silico and In Vitro Approach

Efflux pumps are one of the predominant microbial resistant mechanisms leading to the development of multidrug resistance. In Staphylococcus aureus, overexpression of NorA protein enables the efflux of antibiotics belonging to the class of fluoroquinolones and, thus, makes S. aureus resistant. Hence, NorA efflux pumps are being extensively exploited as the potential drug target to evade bacterial resistance and resensitize bacteria to the existing antibiotics. Although several molecules are reported to inhibit NorA efflux pump effectively, boronic acid derivatives were shown to have promising NorA efflux pump inhibition. In this regard, the current study exploits 6-(3-phenylpropoxy)pyridine-3-boronic acid to further improve the activity and reduce cytotoxicity using the bioisostere approach, a classical medicinal chemistry concept. Using the SWISS-Bioisostere online tool, from the parent compound, 42 compounds were obtained upon the replacement of the boronic acid. The 42 compounds were docked with modeled NorA protein, and key molecular interactions of the prominent compounds were assessed. The top hit compounds were further analyzed for their drug-like properties using ADMET studies. The identified potent lead, 5-nitro-2-(3-phenylpropoxy)pyridine (5-NPPP), was synthesized, and in vitro efficacy studies have been proven to show enhanced efflux inhibition, thus acting as a potent antibiotic breaker to resensitize S. aureus without elucidating any cytotoxic effect to the host Hep-G2 cell lines.